Biotech Trevi Nabs $70M In Revised IPO, Private Placement
WilmerHale-led Trevi Therapeutics priced its initial public offering at $10 per share Tuesday, taking in $55 million from the IPO a day after the biotechnology firm cut its target but added...To view the full article, register now.
Already a subscriber? Click here to view full article